Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients

In allogeneic stem cell transplant (Allo-SCT) recipients, the cell-mediated and humoral immunogenicity of the 3-dose SARS-CoV-2 vaccination schedule has not been investigated in prospective studies. In a prospective cohort, we recruited 122 Allo-SCT recipients since August 2021, when Ontario began o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Muneyoshi, Ferreira, Victor H., Kothari, Sagar, Pasic, Ivan, Mattsson, Jonas I., Kulasingam, Vathany, Humar, Atul, Mah, Allison, Delisle, Jean-Sébastien, Ierullo, Matthew, Majchrzak-Kita, Beata, Kumar, Deepali, Hosseini-Moghaddam, Seyed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy. 2022
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334861/
https://www.ncbi.nlm.nih.gov/pubmed/35914727
http://dx.doi.org/10.1016/j.jtct.2022.07.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334861/
https://www.ncbi.nlm.nih.gov/pubmed/35914727
http://dx.doi.org/10.1016/j.jtct.2022.07.024

Ejemplares similares